Latest News on ACAD

Financial News Based On Company


Advertisement
Advertisement

Can Auvelity Drive Axsome's Growth Through the Rest of 2025?

https://www.zacks.com/stock/news/2759603/can-auvelity-drive-axsomes-growth-through-the-rest-of-2025
AXSM's Auvelity drives 82% sales growth in the first half of 2025, with label expansion studies and other marketed products bolstering its CNS drug portfolio.

ACAD Stock Down 10% Following Phase III Hyperphagia Study Failure

https://www.zacks.com/stock/news/2757116/acad-stock-down-10-following-phase-iii-hyperphagia-study-failure
Acadia Pharmaceuticals stock tumbles 10% after its phase III hyperphagia study failure, but growth remains driven by Nuplazid, Daybue and a robust pipeline.

Acadia Pharma Faces Trial Setback As Prader-Willi Syndrome Trial Falls Short - ACADIA Pharmaceuticals ( NASDAQ:ACAD )

https://www.benzinga.com/news/health-care/25/09/47841758/acadia-pharma-faces-trial-setback-as-prader-willi-syndrome-trial-falls-short
Acadia Pharmaceuticals Inc. ACAD released topline results on Wednesday from its Phase 3 COMPASS PWS trial evaluating the efficacy and safety of intranasal carbetocin ( ACP-101 ) in patients with hyperphagia in Prader-Willi syndrome ( PWS ) .

ACADIA Pharmaceuticals EVP Trades $82K In Company Stock - ACADIA Pharmaceuticals ( NASDAQ:ACAD )

https://www.benzinga.com/insights/news/25/09/47717575/acadia-pharmaceuticals-evp-trades-82k-in-company-stock
Mark Schneyer, EVP at ACADIA Pharmaceuticals ACAD, reported an insider sell on September 16, according to a new SEC filing. What Happened: Schneyer's decision to sell 3,498 shares of ACADIA Pharmaceuticals was revealed in a Form 4 filing with the U.S. Securities and Exchange Commission on Tuesday.

Axsome Shares Up 20% in a Month: How Should You Play the Stock?

https://www.zacks.com/stock/news/2745115/axsome-shares-up-20-in-a-month-how-should-you-play-the-stock
AXSM shares rise 20.2% in a month, powered by booming Auvelity sales and a growing CNS drug pipeline.
Advertisement

Is First Trust NYSE Arca Biotechnology ETF ( FBT ) a Strong ETF Right Now?

https://www.zacks.com/stock/news/2743220/is-first-trust-nyse-arca-biotechnology-etf-fbt-a-strong-etf-right-now
Smart Beta ETF report for ...

JAZZ Inks $1B Licensing Deal With Saniona for Epilepsy Drug

https://www.zacks.com/stock/news/2740823/jazz-inks-1b-licensing-deal-with-saniona-for-epilepsy-drug
Jazz Pharmaceuticals strikes a $1B licensing deal with Saniona for SAN2355, an epilepsy drug designed to target seizure control more precisely.

Cytokinetics Names Jim Daly to Board of Directors

https://www.globenewswire.com/news-release/2025/08/20/3136325/35409/en/Cytokinetics-Names-Jim-Daly-to-Board-of-Directors.html
SOUTH SAN FRANCISCO, Calif., Aug. 20, 2025 ( GLOBE NEWSWIRE ) -- Cytokinetics, Incorporated ( Nasdaq: CYTK ) today announced the appointment of James M. Daly to its Board of Directors effective August 19, 2025. Mr. Daly brings over 30 years of global biopharmaceutical leadership experience with ...

Cytokinetics Names Jim Daly to Board of Directors - Cytokinetics ( NASDAQ:CYTK )

https://www.benzinga.com/pressreleases/25/08/g47230543/cytokinetics-names-jim-daly-to-board-of-directors
SOUTH SAN FRANCISCO, Calif., Aug. 20, 2025 ( GLOBE NEWSWIRE ) -- Cytokinetics, Incorporated CYTK today announced the appointment of James M. Daly to its Board of Directors effective August 19, 2025.

Acadia Q2 Earnings Beat, Nuplazid & Daybue Sales Drive Revenue Growth

https://www.zacks.com/stock/news/2678891/acadia-q2-earnings-beat-nuplazid-daybue-sales-drive-revenue-growth
ACAD reports encouraging second-quarter results as earnings and revenues beat estimates, driven by year-over-year growth in Nuplazid and Daybue sales.
Advertisement

Acadia ( ACAD ) Q2 Revenue Rises 9%

https://www.fool.com/data-news/2025/08/07/acadia-acad-q2-revenue-rises-9/
Acadia Pharmaceuticals ( NASDAQ:ACAD ) , a neuroscience-focused biopharma company behind treatments for central nervous system diseases, reported its earnings for Q2 2025 on August 6, 2025. The most notable news was a slight beat on both GAAP earnings and revenue, driven by ongoing growth in its ...

Acadia Pharmaceuticals ( ACAD ) Tops Q2 Earnings and Revenue Estimates

https://www.zacks.com/stock/news/2674909/acadia-pharmaceuticals-acad-tops-q2-earnings-and-revenue-estimates
Acadia (ACAD) delivered earnings and revenue surprises of +14.29% and +1.87%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

Adaptive Biotechnologies ( ADPT ) Reports Q2 Loss, Beats Revenue Estimates

https://www.zacks.com/stock/news/2669731/adaptive-biotechnologies-adpt-reports-q2-loss-beats-revenue-estimates
Adaptive Biotechnologies (ADPT) delivered earnings and revenue surprises of +29.17% and +18.47%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

Catalyst Pharmaceutics to Report Q2 Earnings: What's in the Cards?

https://www.zacks.com/stock/news/2667522/catalyst-pharmaceutics-to-report-q2-earnings-whats-in-the-cards
CPRX gears up to report Q2 results as Firdapse sales rise, Agamree grows, and Fycompa faces a post-patent dip.

Recursion Pharmaceuticals to Report Q2 Earnings: What's in the Cards?

https://www.zacks.com/stock/news/2663146/recursion-pharmaceuticals-to-report-q2-earnings-whats-in-the-cards
RXRX eyes Q2 earnings beat despite past misses, with a refocused pipeline and new data updates on key drug candidates.
Advertisement

Sarepta to Report Q2 Earnings: What's in Store for the Stock?

https://www.zacks.com/stock/news/2663061/sarepta-to-report-q2-earnings-whats-in-store-for-the-stock
SRPT's Q2 report, set to arrive Aug. 6, is likely to have Elevidys updates, restructuring plans and sales outlook in sharp investor focus.

GMAB vs. ACAD: Which Stock Is the Better Value Option?

https://www.zacks.com/stock/news/2649812/gmab-vs-acad-which-stock-is-the-better-value-option
Investors with an interest in Medical - Biomedical and Genetics stocks have likely encountered both Genmab A/S Sponsored ADR ( GMAB Quick QuoteGMAB - ) and Acadia Pharmaceuticals ( ACAD Quick QuoteACAD - ) . But which of these two stocks offers value investors a better bang for their buck right ...

Acadia Pharmaceuticals ( ACAD ) Expected to Beat Earnings Estimates: Should You Buy?

https://www.zacks.com/stock/news/2638893/acadia-pharmaceuticals-acad-expected-to-beat-earnings-estimates-should-you-buy
Acadia (ACAD) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

After Falling 68%, Where Will This Weight-Loss Drug Stock Be in 2 Years? History Shows Massive Gains Ahead.

https://www.fool.com/investing/2025/07/19/after-falling-68-where-will-this-weight-loss-drug/
Yet another biopharma name has been run through a familiar trading cycle that often ends on a bullish note.

KMDA or ACAD: Which Is the Better Value Stock Right Now?

https://www.zacks.com/stock/news/2563501/kmda-or-acad-which-is-the-better-value-stock-right-now
KMDA vs. ACAD: Which Stock Is the Better Value Option?
Advertisement

Is First Trust NYSE Arca Biotechnology ETF ( FBT ) a Strong ETF Right Now?

https://www.zacks.com/stock/news/2542468/is-first-trust-nyse-arca-biotechnology-etf-fbt-a-strong-etf-right-now
Smart Beta ETF report for ...

KMDA vs. ACAD: Which Stock Is the Better Value Option?

https://www.zacks.com/stock/news/2511135/kmda-vs-acad-which-stock-is-the-better-value-option
Investors looking for stocks in the Medical - Biomedical and Genetics sector might want to consider either Kamada ( KMDA Quick QuoteKMDA - ) or Acadia Pharmaceuticals ( ACAD Quick QuoteACAD - ) . But which of these two stocks is more attractive to value investors? We'll need to take a closer look ...

JPMorgan Lifts Acadia Price Target After Nuplazid Patent Victory - ACADIA Pharmaceuticals ( NASDAQ:ACAD )

https://www.benzinga.com/analyst-stock-ratings/price-target/25/06/45822460/jpmorgan-lifts-acadia-price-target-after-nuplazid-patent-victory
Court ruling secures Nuplazid's 34 mg formulation patent protection through 2038. JPMorgan hikes Acadia target from $26 to $30, citing strong patent outlook. Get access to the leaderboards pointing to tomorrow's biggest stock movers. In May, the U.S.

Why Is Acadia ( ACAD ) Up 26.1% Since Last Earnings Report?

https://www.zacks.com/stock/news/2487642/why-is-acadia-acad-up-261-since-last-earnings-report
Acadia (ACAD) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

GSK or ACAD: Which Is the Better Value Stock Right Now?

https://www.zacks.com/stock/news/2474138/gsk-or-acad-which-is-the-better-value-stock-right-now
GSK vs. ACAD: Which Stock Is the Better Value Option?
Advertisement

ACAD Stock Soars as US Court Rules in Favor of Key Nuplazid Patent

https://www.zacks.com/stock/news/2474014/acad-stock-soars-as-us-court-rules-in-favor-of-key-nuplazid-patent
Acadia stock jumps 27% after winning a key patent case for Nuplazid, which will protect the drug's U.S. sales from generic erosion till 2038.

These Analysts Boost Their Forecasts On Acadia Pharmaceuticals - ACADIA Pharmaceuticals ( NASDAQ:ACAD )

https://www.benzinga.com/25/05/45491578/these-analysts-boost-their-forecasts-on-acadia-pharmaceuticals
ACADIA Pharmaceuticals Inc ACAD announced a favorable court ruling on Friday. The U.S. District Court for the District of Delaware upheld the validity and found infringement of Acadia's '721 formulation patent for NUPLAZID ( pimavanserin ) , a treatment for Parkinson's Disease Psychosis.

Netflix To $1,220? Here Are 10 Top Analyst Forecasts For Monday - Archer-Daniels-Midland ( NYSE:ADM ) , ACADIA Pharmaceuticals ( NASDAQ:ACAD )

https://www.benzinga.com/25/05/45490633/netflix-to-1220-here-are-10-top-analyst-forecasts-for-monday
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page. Needham raised ACADIA Pharmaceuticals Inc. ACAD price target from $27 to $30.

Acadia Pharmaceuticals ( ACAD ) Stock Explodes 26% After Patent Court Victory - ACADIA Pharmaceuticals ( NASDAQ:ACAD )

https://www.benzinga.com/news/25/05/45476079/acadia-pharmaceuticals-acad-stock-explodes-26-after-patent-court-victory
ACADIA Pharmaceuticals stock jumped 26.4% Friday afternoon. Shares gained following a favorable court ruling. Discover the top trade setups and strategies beating the S&P this year -live this Wednesday at 6 PM ET. Reserve your free spot now.

Evolv Technologies, Quantum Computing, ACADIA Pharmaceuticals And Other Big Stocks Moving Higher On Friday - Archer Aviation ( NYSE:ACHR ) , ACADIA Pharmaceuticals ( NASDAQ:ACAD )

https://www.benzinga.com/25/05/45470960/evolv-technologies-quantum-computing-acadia-pharmaceuticals-and-other-big-stocks-moving-higher-on-friday
U.S. stocks were mixed, with the Dow Jones index gaining around 0.1% on Friday. Shares of Evolv Technologies Holdings, Inc. EVLV rose sharply during Friday's session after the company announced preliminary first-quarter financial results. The company said it expects revenue growth of 40%+ in the ...
Advertisement

Acadia Pharmaceuticals ( ACAD ) Tops Q1 Earnings and Revenue Estimates ( Revised )

https://www.zacks.com/stock/news/2466428/acadia-pharmaceuticals-acad-tops-q1-earnings-and-revenue-estimates-revised
Acadia (ACAD) delivered earnings and revenue surprises of 10% and 1.23%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?

Acadia Q1 Earnings Beat, Nuplazid & Daybue Sales Drive Revenue Growth

https://www.zacks.com/stock/news/2465350/acadia-q1-earnings-beat-nuplazid-daybue-sales-drive-revenue-growth
ACAD reports encouraging first-quarter results as earnings and revenues beat estimates, driven by year-over-year growth in Nuplazid and Daybue sales.

Acadia Pharmaceuticals ( ACAD ) Tops Q1 Earnings and Revenue Estimates

https://www.zacks.com/stock/news/2464473/acadia-pharmaceuticals-acad-tops-q1-earnings-and-revenue-estimates
Acadia (ACAD) delivered earnings and revenue surprises of 10% and 1.23%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?

DENTSPLY SIRONA to Post Q1 Earnings: What's in Store for the Stock?

https://www.zacks.com/stock/news/2462221/dentsply-sirona-to-post-q1-earnings-whats-in-store-for-the-stock
XRAY is likely to have faced a tough first quarter with Byte's revenue loss, weak U.S. equipment demands and implant pressures.

Analysts Estimate Fortrea Holdings Inc. ( FTRE ) to Report a Decline in Earnings: What to Look Out for

https://www.zacks.com/stock/news/2462131/analysts-estimate-fortrea-holdings-inc-ftre-to-report-a-decline-in-earnings-what-to-look-out-for
Fortrea Holdings Inc. (FTRE) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Advertisement

5 Drug/Biotech Stocks Likely to Outperform Q1 Earnings Estimates

https://www.zacks.com/stock/news/2462159/5-drugbiotech-stocks-likely-to-outperform-q1-earnings-estimates
Let us look at some drug/biotech stocks, NVO, PCRX, RARE, ACAD and DNLI, which are poised to beat on first-quarter 2025 earnings.

Earnings Preview: Acadia Pharmaceuticals ( ACAD ) Q1 Earnings Expected to Decline

https://www.zacks.com/stock/news/2459056/earnings-preview-acadia-pharmaceuticals-acad-q1-earnings-expected-to-decline
Acadia (ACAD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Acadia ( ACAD ) Stock Jumps 6.1%: Will It Continue to Soar?

https://www.zacks.com/stock/news/2443317/acadia-acad-stock-jumps-61-will-it-continue-to-soar
Acadia (ACAD) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

Alector Provides Executive Leadership Update - Alector ( NASDAQ:ALEC )

https://www.benzinga.com/pressreleases/25/03/g44545387/alector-provides-executive-leadership-update
--Giacomo Salvadore, M.D., appointed Chief Medical Officer-- --Gary Romano, M.D., Ph.D., to transition from Chief Medical Officer role-- SOUTH SAN FRANCISCO, Calif., March 28, 2025 ( GLOBE NEWSWIRE ) -- Alector, Inc.

Alector Provides Executive Leadership Update

https://www.globenewswire.com/news-release/2025/03/28/3051632/0/en/Alector-Provides-Executive-Leadership-Update.html
--Giacomo Salvadore, M.D., appointed Chief Medical Officer-- --Gary Romano, M.D., Ph.D., to transition from Chief Medical Officer ...
Advertisement

Why Is Acadia ( ACAD ) Down 11.1% Since Last Earnings Report?

https://www.zacks.com/stock/news/2436979/why-is-acadia-acad-down-111-since-last-earnings-report
Acadia (ACAD) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

SLNO Stock Rallies on FDA Approval of Prader-Willi Syndrome Drug

https://www.zacks.com/stock/news/2436034/slno-stock-rallies-on-fda-approval-of-prader-willi-syndrome-drug
Soleno's shares soar in the premarket hours following the FDA approval of Vykat XR (diazoxide choline) for treating hyperphagia in PWS patients.

Will Auvelity & Other Drugs Aid AXSM's Growth Amid Stiff Competition?

https://www.zacks.com/stock/news/2430290/will-auvelity-other-drugs-aid-axsms-growth-amid-stiff-competition
Axsome's depression drug, Auvelity, is driving the top line while Sunosi diversifies its business. The recent FDA nod for Symbravo also bodes well.

Acadia Pharmaceuticals ( ACAD ) Q4 Earnings Lag Estimates ( Revised )

https://www.zacks.com/stock/news/2425672/acadia-pharmaceuticals-acad-q4-earnings-lag-estimates-revised
Acadia (ACAD) delivered earnings and revenue surprises of -10.53% and 1.79%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?

Acadia's Q4 Earnings Miss, Nuplazid & Daybue Drive Revenue Growth ( Revised )

https://www.zacks.com/stock/news/2424877/acadias-q4-earnings-miss-nuplazid-daybue-drive-revenue-growth-revised
ACAD reports mixed fourth-quarter results as earnings missed estimates while revenues beat the same, driven by year-over-year growth in Nuplazid and Daybue sales.
Advertisement

Acadia's Q4 Earnings Miss, Nuplazid & Daybue Drive Revenue Growth

https://www.zacks.com/stock/news/2422991/acadias-q4-earnings-miss-nuplazid-daybue-drive-revenue-growth
ACAD reports mixed fourth-quarter results as earnings missed estimates while revenues beat the same, driven by year-over-year growth in Nuplazid and Daybue sales.

Acadia Pharmaceuticals ( ACAD ) Q4 Earnings Lag Estimates

https://www.zacks.com/stock/news/2422255/acadia-pharmaceuticals-acad-q4-earnings-lag-estimates
Acadia (ACAD) delivered earnings and revenue surprises of -10.53% and 1.79%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?

Is the Options Market Predicting a Spike in ACADIA Pharmaceuticals ( ACAD ) Stock?

https://www.zacks.com/stock/news/2415187/is-the-options-market-predicting-a-spike-in-acadia-pharmaceuticals-acad-stock
Investors need to pay close attention to ACADIA Pharmaceuticals (ACAD) stock based on the movements in the options market lately.

Blueprint Medicines ( BPMC ) Reports Q4 Loss, Misses Revenue Estimates

https://www.zacks.com/stock/news/2415188/blueprint-medicines-bpmc-reports-q4-loss-misses-revenue-estimates
Blueprint Medicines (BPMC) delivered earnings and revenue surprises of -12.86% and 0.79%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?

Should You Invest in the First Trust NYSE Arca Biotechnology ETF ( FBT ) ?

https://www.zacks.com/stock/news/2412442/should-you-invest-in-the-first-trust-nyse-arca-biotechnology-etf-fbt
Sector ETF report for ...
Advertisement
Advertisement
Advertisement
Advertisement

Sign Up free to view live trades and discussion forum to make more informed financial decisions. No credit card is required for sign up!
View Daily Trades
Join Discussion

Advertisement
Advertisement
Advertisement
Advertisement